Kolexia
Lindet Bourgeois Clothilde
Oncologie médicale
Hôpital Saint-Éloi
Montpellier, France
36 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémangiosarcome Sarcomes Tumeurs de l'ovaire Tumeurs osseuses Carcinomes Néphrocarcinome Leucémie à tricholeucocytes Leucémies Tumeurs du foie

Industries

Ipsen
4 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2020
MSD
2 collaboration(s)
Dernière en 2023

Dernières activités

Differential Sensitivity of Germline and Somatic Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer.
International journal of molecular sciences   16 septembre 2023
PRISM care: Impact of the PRISM-care Multidisciplinary Oncology Program Versus Usual Care on Secured Drug Intake of Patients With Kidney Cancer, Through Self-management of Adverse Events Related to Oral Targeted Therapies, Control of Drug Interactions, and Sharing of the Information Between Ambulatory and Hospital Settings.
Essai Clinique (Hospices Civils de Lyon)   22 avril 2022
Ovarian Clear Cell Carcinoma in Cowden Syndrome.
Journal of the National Comprehensive Cancer Network : JNCCN   22 juin 2020
Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial
Blood   08 décembre 2017
Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO).
European journal of cancer (Oxford, England : 1990)   08 septembre 2012
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.
The International journal of biological markers   19 juillet 2012
Localized angiosarcomas (AS): Identification of prognostic factors (PF) and analysis of treatment impact—Series from the French Sarcoma Group (GSF/GETO).
2012 ASCO Annual Meeting I   20 mai 2012
Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide.
Acta oncologica (Stockholm, Sweden)   29 juillet 2010
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}